Novo Nordisk rises as Wegovy pill rolls out in Germany
Novo Nordisk rose about 0.5% to $45.545 after rolling out its Wegovy pill in Germany, bringing the oral weight-loss treatment to the EU’s largest pharmaceutical market.
Novo Nordisk NYSE:NVO gained about 0.5% to $45.545 on Tuesday after the company rolled out the Wegovy pill in Germany. The move puts Novo Nordisk's oral weight-loss treatment into the European Union's largest pharmaceutical market and gives Germany the EU's first taste of the product.